BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9. [PMID: 20008645 DOI: 10.1200/JCO.2008.20.7019] [Cited by in Crossref: 365] [Cited by in F6Publishing: 173] [Article Influence: 30.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang CJ, Xu Y, Lin Y, Zhu HJ, Zhou YD, Mao F, Zhang XH, Huang X, Zhong Y, Sun Q, Li CG. Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis. Front Oncol 2020;10:592998. [PMID: 33304851 DOI: 10.3389/fonc.2020.592998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer 2021;124:552-63. [PMID: 33106584 DOI: 10.1038/s41416-020-01114-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
3 Fasching PA, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, Polley EC, Lee KY, Gnanaolivu RD, Hadji P, Hübner H, Tesch H, Ettl J, Overkamp F, Lux MP, Ekici AB, Volz B, Uhrig S, Lüftner D, Wallwiener M, Müller V, Belleville E, Untch M, Kolberg HC, Beckmann MW, Reis A, Hartmann A, Janni W, Wimberger P, Taran FA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD, Couch FJ. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021;39:1619-30. [PMID: 33780288 DOI: 10.1200/JCO.20.01200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hatano Y, Tamada M, Matsuo M, Hara A. Molecular Trajectory of BRCA1 and BRCA2 Mutations. Front Oncol 2020;10:361. [PMID: 32269964 DOI: 10.3389/fonc.2020.00361] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
5 Cusin I, Teixeira D, Zahn-Zabal M, Rech de Laval V, Gleizes A, Viassolo V, Chappuis PO, Hutter P, Bairoch A, Gaudet P. A new bioinformatics tool to help assess the significance of BRCA1 variants. Hum Genomics 2018;12:36. [PMID: 29996917 DOI: 10.1186/s40246-018-0168-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5. [PMID: 21819606 DOI: 10.1186/1897-4287-9-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, Rochlitz C, Zanetti-Dällenbach R. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget 2017;8:75617-26. [PMID: 29088896 DOI: 10.18632/oncotarget.18118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110. [PMID: 22082486 DOI: 10.2174/156652412798376134] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 13.3] [Reference Citation Analysis]
9 Hámori L, Kudlik G, Szebényi K, Kucsma N, Szeder B, Póti Á, Uher F, Várady G, Szüts D, Tóvári J, Füredi A, Szakács G. Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line. Int J Mol Sci 2020;21:E1185. [PMID: 32053991 DOI: 10.3390/ijms21041185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Maleva I, Madjunkova S, Bozhinovski G, Smickova E, Kondov G, Spiroski Z, Arsovski A, Plaseska-Karanfilska D. Genetic variation of the brca1 and brca2 genes in macedonian patients. Balkan J Med Genet 2012;15:81-5. [PMID: 24052750 DOI: 10.2478/v10034-012-0025-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A, Zacksenhaus E. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One. 2013;8:e78641. [PMID: 24265703 DOI: 10.1371/journal.pone.0078641] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
12 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
13 Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012;21:151-61. [PMID: 22134580 DOI: 10.1007/s10897-011-9462-x] [Cited by in Crossref: 211] [Cited by in F6Publishing: 139] [Article Influence: 21.1] [Reference Citation Analysis]
14 Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014;16:475. [PMID: 25475740 DOI: 10.1186/s13058-014-0475-x] [Cited by in Crossref: 163] [Cited by in F6Publishing: 133] [Article Influence: 23.3] [Reference Citation Analysis]
15 Li SX, Sjolund A, Harris L, Sweasy JB. DNA repair and personalized breast cancer therapy. Environ Mol Mutagen 2010;51:897-908. [PMID: 20872853 DOI: 10.1002/em.20606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
16 Parmar V, Nair NS, Thakkar P, Chitkara G. Molecular Biology in the Breast Clinics-Current status and future perspectives. Indian J Surg Oncol 2021;12:7-20. [PMID: 33994723 DOI: 10.1007/s13193-019-00954-1] [Reference Citation Analysis]
17 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
18 Kotsopoulos JBRCA Mutations and breast cancer prevention. Cancers (Basel). 2018;10. [PMID: 30572612 DOI: 10.3390/cancers10120524] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
19 Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615-2623. [PMID: 22665533 DOI: 10.1200/jco.2010.34.5579] [Cited by in Crossref: 304] [Cited by in F6Publishing: 179] [Article Influence: 33.8] [Reference Citation Analysis]
20 Pouptsis A, Swafe L, Patwardhan M, Stavraka C. Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations. Front Oncol 2020;10:553080. [PMID: 33194613 DOI: 10.3389/fonc.2020.553080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Liu X, Li H, Shao B, Wu J, Kong W, Song G, Jiang H, Wang J, Wan F. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Med 2017;6:547-54. [PMID: 28135048 DOI: 10.1002/cam4.1004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47. [PMID: 21709140 DOI: 10.1093/annonc/mdr304] [Cited by in Crossref: 2110] [Cited by in F6Publishing: 1717] [Article Influence: 211.0] [Reference Citation Analysis]
23 Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y, Hu Z, Liu B, Chen X. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PLoS One 2013;8:e52589. [PMID: 23326344 DOI: 10.1371/journal.pone.0052589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
24 Moghadas-Dastjerdi H, Sha-E-Tallat HR, Sannachi L, Sadeghi-Naini A, Czarnota GJ. A priori prediction of tumour response to neoadjuvant chemotherapy in breast cancer patients using quantitative CT and machine learning. Sci Rep 2020;10:10936. [PMID: 32616912 DOI: 10.1038/s41598-020-67823-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010;4:284-300. [PMID: 20466604 DOI: 10.1016/j.molonc.2010.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
26 Zhao EY, Jones M, Jones SJM. Whole-Genome Sequencing in Cancer. Cold Spring Harb Perspect Med 2019;9:a034579. [PMID: 29844223 DOI: 10.1101/cshperspect.a034579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978. [PMID: 22461984 DOI: 10.1155/2012/385978] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
28 Su YW, Hung CY, Lam HB, Chang YC, Yang PS. A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status. Clin Med Insights Oncol 2018;12:1179554918794672. [PMID: 30150877 DOI: 10.1177/1179554918794672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 Lee JS, Yost SE, Yuan Y. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. Cancers (Basel) 2020;12:E1404. [PMID: 32486021 DOI: 10.3390/cancers12061404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
30 Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14:409-414. [PMID: 22522501 DOI: 10.1038/aja.2011.150] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
31 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
32 Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42. [PMID: 20979652 DOI: 10.1186/1756-8722-3-42] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
33 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014;25:1871-88. [PMID: 25234545 DOI: 10.1093/annonc/mdu385] [Cited by in Crossref: 252] [Cited by in F6Publishing: 217] [Article Influence: 36.0] [Reference Citation Analysis]
34 Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F, Wang D, Chen W, Huang O, Chen X, Wu J, Shen K, Loo WT, Chow LW. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med 2012;10 Suppl 1:S4. [PMID: 23046633 DOI: 10.1186/1479-5876-10-S1-S4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
35 Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 2012;29:807-19. [PMID: 22692561 DOI: 10.1007/s10585-012-9496-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
36 Larsen MJ, Thomassen M, Gerdes AM, Kruse TA. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) 2014;8:145-55. [PMID: 25368521 DOI: 10.4137/BCBCR.S18715] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
37 Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 2016;22:2855-64. [PMID: 26801247 DOI: 10.1158/1078-0432.CCR-15-2137] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 8.4] [Reference Citation Analysis]
38 Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel) 2018;10:E506. [PMID: 30544963 DOI: 10.3390/cancers10120506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
39 Bougie O, Weberpals JI. Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol 2011;2011:374012. [PMID: 22312502 DOI: 10.1155/2011/374012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
40 Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. Nat Commun. 2017;8:15981. [PMID: 28714471 DOI: 10.1038/ncomms15981] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
41 Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol 2020;38:1539-48. [PMID: 32097092 DOI: 10.1200/JCO.19.03292] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 28.0] [Reference Citation Analysis]
42 Alshabi AM, Shaikh IA, Vastrad C; BasavarajVastrad. Exploring the Molecular Mechanism of the Drug-Treated Breast Cancer Based on Gene Expression Microarray. Biomolecules 2019;9:E282. [PMID: 31311202 DOI: 10.3390/biom9070282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ribeiro J, Sousa B, Cardoso F. Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl 2013;11:3-22. [PMID: 26217109 DOI: 10.1016/j.ejcsup.2013.07.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Dębska-Szmich S, Krakowska M, Czernek U, Habib-Lisik M, Zięba A, Potemski P. The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol (Pozn) 2016;20:93-101. [PMID: 27358586 DOI: 10.5114/wo.2016.60067] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet 2015;6:96. [PMID: 25852742 DOI: 10.3389/fgene.2015.00096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
46 Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 2011;11:7. [PMID: 21771338 DOI: 10.1186/1471-2210-11-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
47 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
48 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 2016;115:1157-73. [PMID: 27736844 DOI: 10.1038/bjc.2016.311] [Cited by in Crossref: 113] [Cited by in F6Publishing: 92] [Article Influence: 22.6] [Reference Citation Analysis]
49 Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010;16:6159-68. [PMID: 20802015 DOI: 10.1158/1078-0432.CCR-10-1027] [Cited by in Crossref: 210] [Cited by in F6Publishing: 108] [Article Influence: 19.1] [Reference Citation Analysis]
50 Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 2015;8:519-28. [PMID: 25750544 DOI: 10.2147/OTT.S30793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
51 Jung J, Kang E, Gwak JM, Seo AN, Park SY, Lee AS, Baek H, Chae S, Kim EK, Kim SW. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol 2016;23:298-303. [PMID: 27803593 DOI: 10.3747/co.23.3054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
52 Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017;152:1048-1056. [PMID: 28700784 DOI: 10.1001/jamasurg.2017.2227] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
53 Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). Cancers (Basel) 2019;11:E1137. [PMID: 31398896 DOI: 10.3390/cancers11081137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Imyanitov E, Sokolenko A. Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. World J Clin Oncol 2021;12:544-56. [PMID: 34367927 DOI: 10.5306/wjco.v12.i7.544] [Reference Citation Analysis]
55 Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C, Hartmann A, Häberle L, Pretscher J, Erber R, Wachter DL, Schulz-Wendtland R, Beckmann MW, Fasching PA, Wunderle M. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer 2018;18:1051. [PMID: 30373556 DOI: 10.1186/s12885-018-4925-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
56 Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 2014;7:866-70. [PMID: 24527094 DOI: 10.3892/ol.2014.1782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
57 Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol 2010;80:647-53. [PMID: 20510205 DOI: 10.1016/j.bcp.2010.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
58 Liu Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer. BMC Cancer 2015;15:194. [PMID: 25884806 DOI: 10.1186/s12885-015-1203-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
59 Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer. 2016;15:359-366. [PMID: 26873719 DOI: 10.1007/s10689-016-9883-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
60 Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, Huang O, He JR, Chen W, Li Y, Shen K, Zhu L. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget 2016;7:31079-87. [PMID: 27145269 DOI: 10.18632/oncotarget.9075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
61 Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D. Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Frauenheilkd 2019;79:1309-19. [PMID: 31875860 DOI: 10.1055/a-1039-4458] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
62 Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E. HRness in Breast and Ovarian Cancers. Int J Mol Sci 2020;21:E3850. [PMID: 32481735 DOI: 10.3390/ijms21113850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
63 Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. Oncotarget 2016;7:80363-72. [PMID: 27385001 DOI: 10.18632/oncotarget.10345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
64 Vargas AC, Reis-Filho JS, Lakhani SR. Phenotype-genotype correlation in familial breast cancer. J Mammary Gland Biol Neoplasia 2011;16:27-40. [PMID: 21400086 DOI: 10.1007/s10911-011-9204-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
65 Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep 2013;5. [PMID: 24416469 DOI: 10.1007/s12609-013-0125-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
66 Gao M, Wang T, Ji L, Bai S, Tian L, Song H. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer. Front Immunol 2020;11:366. [PMID: 32194569 DOI: 10.3389/fimmu.2020.00366] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
67 Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627-636. [PMID: 21161370 DOI: 10.1007/s10549-010-1293-1] [Cited by in Crossref: 194] [Cited by in F6Publishing: 180] [Article Influence: 17.6] [Reference Citation Analysis]
68 Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013;18:909-16. [PMID: 23881989 DOI: 10.1634/theoncologist.2013-0039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
69 Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011;29:3739-46. [PMID: 21900106 DOI: 10.1200/JCO.2011.35.2682] [Cited by in Crossref: 113] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
70 Murthy P, Muggia F. Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. Ecancermedicalscience 2019;13:904. [PMID: 30915162 DOI: 10.3332/ecancer.2019.904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
71 Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann PU, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching PA, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Krockenberger M. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd 2018;78:927-48. [PMID: 30369626 DOI: 10.1055/a-0646-4522] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
72 Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010;32:25-33. [PMID: 21778580 DOI: 10.3233/bd-2010-0306] [Cited by in Crossref: 68] [Cited by in F6Publishing: 45] [Article Influence: 7.6] [Reference Citation Analysis]
73 Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. Mol Clin Oncol 2015;3:720-4. [PMID: 26137293 DOI: 10.3892/mco.2015.518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
74 Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Res Treat 2014;144:133-42. [PMID: 24477976 DOI: 10.1007/s10549-014-2842-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
75 Agnese DM, Pollock RE. Breast Cancer Genetic Counseling: A Surgeon's Perspective. Front Surg 2016;3:4. [PMID: 26858951 DOI: 10.3389/fsurg.2016.00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
76 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
77 Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58. [PMID: 21080741 DOI: 10.2165/11538150-000000000-00000] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
78 Elaimy AL, Amante JJ, Zhu LJ, Wang M, Walmsley CS, FitzGerald TJ, Goel HL, Mercurio AM. The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression. Proc Natl Acad Sci U S A 2019;116:14174-80. [PMID: 31235595 DOI: 10.1073/pnas.1821194116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
79 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
80 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
81 Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study. BMC Cancer 2016;16:811. [PMID: 27756336 DOI: 10.1186/s12885-016-2848-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
82 Bhattacharyya GS, Walia M, Nandi M, Murli A, Salim S, Rajpurohit S, Shinde S, Aggarwal S, Parikh PM. Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer. South Asian J Cancer 2018;7:156-8. [PMID: 29721485 DOI: 10.4103/sajc.sajc_126_18] [Reference Citation Analysis]
83 Wunderle M, Häberle L, Hein A, Jud SM, Lux MP, Hack CC, Emons J, Heindl F, Nabieva N, Loehberg CR, Schulz-Wendtland R, Hartmann A, Beckmann MW, Fasching PA, Gass P. Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care (Basel) 2021;16:254-62. [PMID: 34248466 DOI: 10.1159/000507475] [Reference Citation Analysis]
84 Heijink AM, Everts M, Honeywell ME, Richards R, Kok YP, de Vries EGE, Lee MJ, van Vugt MATM. Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Rep 2019;28:2345-2357.e5. [PMID: 31461651 DOI: 10.1016/j.celrep.2019.07.070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
85 Gorodetska I, Kozeretska I, Dubrovska A. BRCA Genes: The role in genome stability, cancer stemness and therapy resistance. J Cancer. 2019;10:2109-2127. [PMID: 31205572 DOI: 10.7150/jca.30410] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 22.0] [Reference Citation Analysis]
86 La Belle A, Khatib J, Schiemann WP, Vinayak S. Role of Platinum in Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2017;18:68. [PMID: 29110096 DOI: 10.1007/s11864-017-0506-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
87 Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol 2018;23:36-44. [PMID: 28884397 DOI: 10.1007/s10147-017-1182-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
88 Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Res Treat 2014;147:185-91. [PMID: 25048467 DOI: 10.1007/s10549-014-3056-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
89 Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 2016;8:93-107. [PMID: 27284266 DOI: 10.2147/BCTT.S69488] [Cited by in Crossref: 37] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
90 Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers. Oncotarget 2016;7:68662-73. [PMID: 27626685 DOI: 10.18632/oncotarget.11900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
91 Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, Tripodo C, Colombo MP, Folli S, de Braud F. Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS One 2019;14:e0220644. [PMID: 31390375 DOI: 10.1371/journal.pone.0220644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. J Oncol 2020;2020:4986365. [PMID: 32963528 DOI: 10.1155/2020/4986365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
93 Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 2014;15:e625-34. [PMID: 25456381 DOI: 10.1016/S1470-2045(14)70364-X] [Cited by in Crossref: 111] [Cited by in F6Publishing: 69] [Article Influence: 15.9] [Reference Citation Analysis]
94 Haynes B, Gajan A, Nangia-Makker P, Shekhar MP. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. Biochim Biophys Acta Mol Basis Dis 2020;1866:165561. [PMID: 31639439 DOI: 10.1016/j.bbadis.2019.165561] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
95 Turner NC, Tutt AN. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res 2012;14:115. [PMID: 23146216 DOI: 10.1186/bcr3332] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
96 Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341-51. [PMID: 20632057 DOI: 10.1007/s10147-010-0106-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
97 Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer 2019;120:398-403. [PMID: 30723304 DOI: 10.1038/s41416-019-0376-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
98 Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013;11:2. [PMID: 23548133 DOI: 10.1186/1897-4287-11-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Klauke ML, Hoogerbrugge N, Budczies J, Bult P, Prinzler J, Radke C, van Krieken JH, Dietel M, Denkert C, Müller BM. Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Arch 2012;461:425-31. [PMID: 22968923 DOI: 10.1007/s00428-012-1311-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
100 Stavropoulou AV, Fostira F, Pertesi M, Tsitlaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, Dimopoulos MA, Timotheadou E, Pectasides D, Christodoulou C, Klouvas G, Papadimitriou C, Makatsoris T, Pentheroudakis G, Aravantinos G, Karydakis V, Yannoukakos D, Fountzilas G, Konstantopoulou I. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One 2013;8:e58182. [PMID: 23536787 DOI: 10.1371/journal.pone.0058182] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
101 Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110. [PMID: 22817698 DOI: 10.1186/bcr3231] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 14.3] [Reference Citation Analysis]
102 Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest 2016;126:2903-18. [PMID: 27454287 DOI: 10.1172/JCI70196] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 13.2] [Reference Citation Analysis]
103 Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017;3:1378-85. [PMID: 28715532 DOI: 10.1001/jamaoncol.2017.1007] [Cited by in Crossref: 150] [Cited by in F6Publishing: 134] [Article Influence: 37.5] [Reference Citation Analysis]
104 Vanags A, Strumfa I, Gardovskis A, Borošenko V, Aboliņš A, Teibe U, Trofimovičs G, Miklaševičs E, Gardovskis J. Population screening for hereditary and familial cancer syndromes in Valka district of Latvia. Hered Cancer Clin Pract 2010;8:8. [PMID: 21034437 DOI: 10.1186/1897-4287-8-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
105 Botesteanu DA, Lipkowitz S, Lee JM, Levy D. Mathematical models of breast and ovarian cancers. Wiley Interdiscip Rev Syst Biol Med 2016;8:337-62. [PMID: 27259061 DOI: 10.1002/wsbm.1343] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
106 Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018;36:2281-7. [PMID: 29791287 DOI: 10.1200/JCO.2017.77.2285] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
107 Sharma P, Zargar-Shoshtari K, Pow-Sang JM. Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA 2016;2:FSO72. [PMID: 28031932 DOI: 10.4155/fso.15.72] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
108 Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes--risk and response. J Mammary Gland Biol Neoplasia. 2011;16:3-15. [PMID: 21461995 DOI: 10.1007/s10911-011-9213-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
109 Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4:1140-53. [PMID: 25096233 DOI: 10.1158/2159-8290.CD-14-0623] [Cited by in Crossref: 327] [Cited by in F6Publishing: 148] [Article Influence: 46.7] [Reference Citation Analysis]
110 Abdel-Fatah TM, Arora A, Moseley PM, Perry C, Rakha EA, Green AR, Chan SY, Ellis IO, Madhusudan S. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget 2015;6:21964-78. [PMID: 26267318 DOI: 10.18632/oncotarget.4157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
111 Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J 2011;17:492-9. [PMID: 22157293 DOI: 10.1097/PPO.0b013e318238f579] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
112 Gorodnova TV, Sokolenko AP, Kotiv KB, Sokolova TN, Ivantsov AO, Guseynov KD, Nekrasova EA, Smirnova OA, Berlev IV, Imyanitov EN. Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. Hered Cancer Clin Pract 2021;19:14. [PMID: 33536037 DOI: 10.1186/s13053-021-00173-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Kołacińska A, Chałubińska J, Błasińska-Morawiec M, Dowgier-Witczak I, Fendler W, Kordek R, Morawiec Z. Pathological complete response in younger and older breast cancer patients. Arch Med Sci 2012;8:310-5. [PMID: 22662005 DOI: 10.5114/aoms.2012.28559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
114 Zong B, Sun L, Peng Y, Wang Y, Yu Y, Lei J, Zhang Y, Guo S, Li K, Liu S. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance. Oncol Rep 2021;46:138. [PMID: 34036395 DOI: 10.3892/or.2021.8089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
115 Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748-57. [PMID: 23569316 DOI: 10.1200/JCO.2012.43.1882] [Cited by in Crossref: 393] [Cited by in F6Publishing: 159] [Article Influence: 49.1] [Reference Citation Analysis]
116 Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol Med 2015;7:438-49. [PMID: 25759362 DOI: 10.15252/emmm.201404580] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
117 Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist 2017;22:655-66. [PMID: 28469042 DOI: 10.1634/theoncologist.2016-0430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
118 Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11. [PMID: 25452441 DOI: 10.1200/JCO.2014.57.1414] [Cited by in Crossref: 342] [Cited by in F6Publishing: 197] [Article Influence: 48.9] [Reference Citation Analysis]
119 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
120 Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers (Basel) 2019;11:E352. [PMID: 30871108 DOI: 10.3390/cancers11030352] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 16.5] [Reference Citation Analysis]
121 Riis ML. Management of patients with BRCA mutation from the point of view of a breast surgeon. Ann Med Surg (Lond) 2021;65:102311. [PMID: 33996049 DOI: 10.1016/j.amsu.2021.102311] [Reference Citation Analysis]
122 Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013;19:6322-8. [PMID: 24077350 DOI: 10.1158/1078-0432.CCR-13-1975] [Cited by in Crossref: 119] [Cited by in F6Publishing: 77] [Article Influence: 14.9] [Reference Citation Analysis]
123 Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin Pharmacokinet 2018;57:427-37. [PMID: 29063517 DOI: 10.1007/s40262-017-0587-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 18.5] [Reference Citation Analysis]
124 Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel. Chem Res Toxicol 2018;31:1293-304. [PMID: 30381944 DOI: 10.1021/acs.chemrestox.8b00170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
125 Huang X, Shao D, Wu H, Zhu C, Guo D, Zhou Y, Chen C, Lin Y, Lu T, Zhao B, Wang C, Sun Q. Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer. Front Oncol 2020;10:583314. [PMID: 33194720 DOI: 10.3389/fonc.2020.583314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Nakamura Y, Yamaue H. Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. Surg Today. 2017;47:65-73. [PMID: 27130464 DOI: 10.1007/s00595-016-1338-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Garcia-Casado Z, Romero I, Fernandez-Serra A, Rubio L, Llopis F, Garcia A, Llombart P, Lopez-Guerrero JA. A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer. BMC Med Genet 2011;12:134. [PMID: 21989022 DOI: 10.1186/1471-2350-12-134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
128 Aitmagambetova M, Smagulova G, Bekmukhambetov Y, Zavalyonnaya O, Tulyaeva A. A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1. Rep Pract Oncol Radiother 2021;26:463-9. [PMID: 34277102 DOI: 10.5603/RPOR.a2021.0069] [Reference Citation Analysis]
129 Davis SL, Eckhardt SG, Tentler JJ, Diamond JR. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 2014;6:88-100. [PMID: 24790649 DOI: 10.1177/1758834013519843] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
130 Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco Targets Ther 2017;10:5739-44. [PMID: 29238206 DOI: 10.2147/OTT.S145934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
131 Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22:1561-70. [PMID: 21135055 DOI: 10.1093/annonc/mdq624] [Cited by in Crossref: 124] [Cited by in F6Publishing: 99] [Article Influence: 11.3] [Reference Citation Analysis]
132 Lachapelle J, Foulkes WD. Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol 2011;18:161-4. [PMID: 21874112 DOI: 10.3747/co.v18i4.824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
133 Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017;18:369-78. [PMID: 28494179 DOI: 10.1080/15384047.2017.1323582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
134 Narod SA. Personalized medicine: a personal view. Curr Oncol 2010;17:4-5. [PMID: 20975871 DOI: 10.3747/co.v17i5.587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Ferté C, André F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol. 2010;7:367-380. [PMID: 20551944 DOI: 10.1038/nrclinonc.2010.84] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
136 Kast K, Rhiem K. Familial breast cancer - targeted therapy in secondary and tertiary prevention. Breast Care (Basel) 2015;10:27-31. [PMID: 25960722 DOI: 10.1159/000380756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
137 Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med 2019;11:e9982. [PMID: 31273933 DOI: 10.15252/emmm.201809982] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
138 Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer. Int J Clin Oncol 2018;23:45-51. [PMID: 29185095 DOI: 10.1007/s10147-017-1208-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
139 Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F. Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. Int J Mol Sci. 2019;20. [PMID: 31295913 DOI: 10.3390/ijms20143390] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
140 Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, Huang J, Zhang Z. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget 2016;7:70113-27. [PMID: 27659521 DOI: 10.18632/oncotarget.12158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
141 Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS. Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers (Basel) 2020;12:E3681. [PMID: 33302444 DOI: 10.3390/cancers12123681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
142 Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 2014;145:707-14. [PMID: 24807107 DOI: 10.1007/s10549-014-2980-0] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 13.0] [Reference Citation Analysis]
143 Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011;3:66-74. [PMID: 21278454 DOI: 10.1093/jmcb/mjq055] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
144 Xu Y, Lin Y, Wang Y, Zhou L, Xu S, Wu Y, Peng J, Zhang J, Yin W, Lu J. Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine 2021;38:101031. [PMID: 34337367 DOI: 10.1016/j.eclinm.2021.101031] [Reference Citation Analysis]
145 Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015;33:1902-1909. [PMID: 25847936 DOI: 10.1200/jco.2014.57.6660] [Cited by in Crossref: 237] [Cited by in F6Publishing: 126] [Article Influence: 39.5] [Reference Citation Analysis]
146 Atipairin A, Ratanaphan A. In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer (Auckl) 2011;5:201-8. [PMID: 22084573 DOI: 10.4137/BCBCR.S8184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
147 Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, Bimbatti D, Massari F, Martignoni G, Tortora G. Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. Target Oncol 2016;11:569-77. [PMID: 27402433 DOI: 10.1007/s11523-016-0450-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
148 Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 2015;24 Suppl 2:S36-40. [PMID: 26253813 DOI: 10.1016/j.breast.2015.07.009] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 10.3] [Reference Citation Analysis]
149 Stecklein SR, Sharma P. Tumor homologous recombination deficiency assays: another step closer to clinical application? Breast Cancer Res 2014;16:409. [PMID: 25928813 DOI: 10.1186/s13058-014-0409-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
150 Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 2010;1:397-412. [PMID: 23199084 DOI: 10.1007/s13167-010-0037-y] [Cited by in Crossref: 120] [Cited by in F6Publishing: 104] [Article Influence: 10.9] [Reference Citation Analysis]
151 Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 2017;4. [PMID: 28706734 DOI: 10.15761/ICST.1000228] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
152 Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017;9:281-92. [PMID: 28808501 DOI: 10.4251/wjgo.v9.i7.281] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
153 Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. Cancer Sci 2018;109:166-73. [PMID: 29047188 DOI: 10.1111/cas.13426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
154 Vollebergh MA, Jonkers J, Linn SC. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 2012;69:223-45. [PMID: 21922196 DOI: 10.1007/s00018-011-0809-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
155 Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, McCoy AS, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol 2018;36:1949-56. [PMID: 29742009 DOI: 10.1200/JCO.2017.75.0158] [Cited by in Crossref: 63] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
156 Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One 2014;9:e108405. [PMID: 25247558 DOI: 10.1371/journal.pone.0108405] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
157 Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, Alexiusdottir KK, Stefansdottir H, Munoz Mitev R, Olafsdottir K, Olafsdottir K, Arason A, Stefansdottir V, Olafsdottir EJ, Barkardottir RB, Eyfjord JE, Narod SA, Tryggvadóttir L. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer 2016;115:776-83. [PMID: 27537391 DOI: 10.1038/bjc.2016.249] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
158 Taleghamar H, Moghadas-Dastjerdi H, Czarnota GJ, Sadeghi-Naini A. Characterizing intra-tumor regions on quantitative ultrasound parametric images to predict breast cancer response to chemotherapy at pre-treatment. Sci Rep 2021;11:14865. [PMID: 34290259 DOI: 10.1038/s41598-021-94004-y] [Reference Citation Analysis]
159 Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012;72:1579-90. [PMID: 22834679 DOI: 10.2165/11635510-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
160 Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int. 2011;108:323-330. [PMID: 21637635 DOI: 10.3238/arztebl.2011.0323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 34] [Article Influence: 0.9] [Reference Citation Analysis]
161 Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, Tung N. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011;117:3093-100. [PMID: 21264845 DOI: 10.1002/cncr.25911] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
162 Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 2012;7:1225-1229. [PMID: 23069641 DOI: 10.4161/epi.22561] [Cited by in Crossref: 88] [Cited by in F6Publishing: 65] [Article Influence: 9.8] [Reference Citation Analysis]
163 Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K, Robson ME. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int 2012;109:713-9. [PMID: 21756279 DOI: 10.1111/j.1464-410X.2011.10292.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
164 Saha P, Nanda R. Concepts and targets in triple-negative breast cancer: recent results and clinical implications. Ther Adv Med Oncol 2016;8:351-9. [PMID: 27583027 DOI: 10.1177/1758834016657071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
165 Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 2014;348:g226. [PMID: 24519767 DOI: 10.1136/bmj.g226] [Cited by in Crossref: 157] [Cited by in F6Publishing: 104] [Article Influence: 22.4] [Reference Citation Analysis]
166 Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer 2014;110:1413-9. [PMID: 24569467 DOI: 10.1038/bjc.2014.81] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
167 Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015;76:489-498. [PMID: 26126726 DOI: 10.1007/s00280-015-2788-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
168 Müller V, Wöckel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Hadji P, Tesch H, Ettl J, Lüftner D, Welslau M, Belleville E, Brucker SY, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Schneeweiss A, Overkamp F. Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018;78:1119-28. [PMID: 30498279 DOI: 10.1055/a-0715-2899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018;19:169-80. [PMID: 29337092 DOI: 10.1016/S1470-2045(17)30891-4] [Cited by in Crossref: 124] [Cited by in F6Publishing: 70] [Article Influence: 41.3] [Reference Citation Analysis]
170 Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, Gardovskis J. Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review. Hered Cancer Clin Pract 2018;16:9. [PMID: 29719582 DOI: 10.1186/s13053-018-0092-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
171 Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S. Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach. Diagnostics (Basel) 2021;11:1144. [PMID: 34201809 DOI: 10.3390/diagnostics11071144] [Reference Citation Analysis]
172 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
173 Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ. Triple Negative Breast Cancer - An Overview. Hereditary Genet. 2013;2013:pii: 001. [PMID: 25285241 DOI: 10.4172/2161-1041.s2-001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]